iDose TR FDA approval date

The FDA approved iDose TR (travoprost intraocular implant) on 13 Dec 2023.

FDA approval date
13 Dec 2023

Drug identity checked against registry records

Also recorded as travoprost intraocular implant

Included trials

TrialSponsorPhaseStatusPrimary completion
Travoprost Intraocular Implant in Conjunction With Cataract SurgeryNCT06061718Glaukos CorporationPhase 3Unknown2024-03-18Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-12-13DayiDose TRFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA218010", "applicant_as_listed_by_fda": "GLAUKOS", "brand_names": ["IDOSE TR"], "active_ingredients": ["TRAVOPROST"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20231213", "matched_on": "drug name equals FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026